Takeda Pharmaceutical
TAK
21.77
+0.36
+1.68%
Takeda Pharmaceutical
US · TAK
#400 by market cap
Listed 1970
21.77
+0.36
+1.68%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/1/30
-
Rating change
TR | OpenAI - 4o Initiates Takeda Pharmaceutical(TAK.US) With Hold Rating, Announces Target Price $15.5Market Newswire · 2025/8/11
-
Rating change
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Raises Target Price to $37.37Market Newswire · 2026/7/31
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Raises Target Price to $21Market Newswire · 2026/3/31
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Maintains Target Price $21Market Newswire · 2026/6/4
-
Company notice
HCK: Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - DATO' DIONG TAK CHONG @ TIONG TAK CHONGBursa Malaysia · 2026/6/29
-
Company notice
OCEAN STAR TECH: PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING (THE "AGM")TO BE HELD AT 10:30 A.M. ON MONDAY, 28 SEPTEMBER 2026 AT ROOM 1606D&E, 16/F., KAI TAK COMMERCIALBUILDING, 317-319 DES VOEUX ROAD CENTRAL, SHEUNG WAN, HONG KONG (OR ANY ADJOURNMENT THEREOF)HKEX · 2026/9/4
-
Company notice
World: Narumiya International accelerates its expansion in the Hong Kong market, with its kids' brand "petit main" opening consecutively at Sogo Causeway Bay and Kai Tak stores.JPX · 2026/5/25
-
[New Launch] Kai Tak Harbour – Double Diamond Adds 71 Units; Net Prices Start at Nearly HK$5.99 Million; Six Units to Be Offered Next TuesdayAASTOCKS · 2026/11/6
-
Rating change
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Maintains Target Price $44.21Market Newswire · 2026/9/15
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Announces Target Price $16Market Newswire · 2025/5/21
-
[Hong Kong Property] Kai Tak Victoria Waterside Records Provisional Sales of Two Units in a Single Day, Generating HK$37.82 Million in ProceedsAASTOCKS · 2026/11/10
-
Rating change
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Announces Target Price $42.65Market Newswire · 2026/8/13
-
Company notice
KING INTL INV: Form of proxy for the Annual General Meeting to be held at 12:00 p.m., Room 3302, 33/F, West Tower, Shun Tak Centre, 200 Connaught Road Central, HongKong on Friday, 4 September 2026.HKEX · 2026/7/31
-
Rating change
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2025/9/9
-
ESMO 2026: TAK-921 Phase III Trial Succeeds; Sone-Ve Demonstrates Significant Overall Survival Benefit in Broad Population, Intensifying Competition in CLDN18.2 ADC SpaceCSOP · 2026/10/26
-
Rating change
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy RatingMarket Newswire · 2026/8/7
-
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Raises Target Price to $50.17Market Newswire · 2026/11/17
-
Company notice
OCEAN STAR TECH: PROXY FORM FOR USE AT THE EXTRAORDINARY GENERAL MEETING (THE "EGM")TO BE HELD AT 10:30 A.M. ON THURSDAY, 12 NOVEMBER 2026 AT ROOM 1606D&E, 16/F., KAI TAK COMMERCIALBUILDING, 317-319 DES VOEUX ROAD CENTRAL, SHEUNG WAN, HONG KONG (OR ANY ADJOURNMENT THEREOF)HKEX · 2026/10/23
-
Eternal Strategy (00764.HK) subsidiary sells Shun Tak Centre property for HK$99.715 millionGelonghui Finance · 2026/11/2
-
Lai Kin Tak Group (08455.HK): Huaan Securities (Hong Kong) Finance Appointed as Independent Financial AdviserGelonghui Finance · 2026/10/20
-
Takeda Pharmaceutical (TAK.US) will release its financial report on October 29.Market Newswire · 2026/10/24
-
Takeda Reports TAK-881 Cuts Infusion Volume 50%, Single-Site Infusion Time 42.6% Vs. HyQvia In Phase 2/3 Immunodeficiency TrialBenzinga · 2026/10/14
-
Rating change
BofA Securities Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating, Raises Target Price to $37.47Market Newswire · 2025/3/10
-
[Hong Kong Property] A four-bedroom unit at The Crown Kai Tak was sold for HK$169 million, translating to a price of HK$79,073 per square foot, setting new records for both transaction price and unit price among standard layouts.AASTOCKS · 2026/9/21
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Takeda Pharmaceutical discussion 0 comments